Only Botulinum Toxin in Canada with an Onset as Early as 24 Hours
TORONTO, April 14, 2014 /CNW/ - Medicis Canada, a division of Valeant Canada, is officially launching Dysport® for use in aesthetic medicine in Canada. One of Europe's leading cosmetic injectables, Dysport® is indicated for temporary improvement in the appearance of moderate to severe glabellar lines in adult patients. In Canada, Dysport® is the only botulinum toxin, a compound derived from a bacterium that inhibits the transmission of nerve impulses to the muscle, with an onset as early as 24 hours for some patients.
First launched in the United Kingdom in 1991, Dysport® is new to Canada, but not to the world of aesthetics. Recognized for its quick onset, and advanced cosmetic technology, Dysport® typically lasts up to four months, providing a soft, smooth and natural look. Dysport® is administered by intramuscular injection and temporarily reduces movement of certain upper facial muscles that cause wrinkles.
"We're delighted to bring Dysport® to Canada and to offer a product that allows patients to look their very best," says Gene Smith, Product Manager, Medicis Canada. "We are confident Canadians who use it will make it their first choice for cosmetic injectables."
Dysport® was launched at an event in Toronto on April 1, featuring acclaimed New York cosmetic dermatologist, Dr. Doris Day of Day Dermatology & Aesthetics. Dr. Day spoke about the many benefits and features of Dysport® and showcased remarkable before-and-after results.
"My patients love the unique features and benefits of Dysport®, including its almost-immediate onset, and that they never look over-done," says Dr. Day. "Dysport® is perfect for people who want to see the product work quickly and to return to their daily activities right away.
As adults age and gravity takes over, the face loses volume and the skin starts to sag and furrow, especially between the eyes. By injecting the glabellar lines, we can soften the lines and gently lift to give a more relaxed appearance and slow the aging process," she continues.
For more information on Dysport®, please visit http://www.dysportcanada.ca/.
The active substance in Dysport® is a botulinum neurotoxin type A complex which acts at the level of the neuromuscular junction in the targeted muscle to block acetylcholine secretion, thereby reducing muscular spasm. It was initially developed to treat motor disorders and various forms of muscular spasticity, including cervical dystonia. Dysport® was later developed for the treatment of a wide variety of neuromuscular disorders, as well as for use in aesthetic medicine. Dysport® has marketing authorization, for aesthetic use, in over 23 countries. In Canada, Dysport® has been approved for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age.
About Valeant Canada
Valeant Canada is a subsidiary of Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. More information about Valeant Canada can be found at www.valeantcanada.com.
SOURCE: Dysport Canada
For further information: visuals, or to arrange an interview, please contact: Amanda Lai, Strategic Objectives, email@example.com, 416-366-7735 ex. 278; Danika Lochhead, Strategic Objectives, firstname.lastname@example.org, 416-366-7735 ex. 290